In line with previous publications reporting the antitumor effect of RHPS4 (Leonetti et al., 2008, Salvati et al., 2007), this drug repressed growth of BRCA2-proficient tumors as assessed by tumor weight inhibition (TWI) (22%, Figure 6D). The gene discussed is BRCA2; the disease is neoplasm.